Mangalam Drugs and Organics Ltd
Incorporated in 1977, Mangalam Drugs
& Organics Ltd manufactures Active Pharmaceutical Ingredients and
Intermediates[1]
- Market Cap ₹ 128 Cr.
- Current Price ₹ 80.7
- High / Low ₹ 145 / 74.4
- Stock P/E 12.5
- Book Value ₹ 93.5
- Dividend Yield 0.00 %
- ROCE %
- ROE %
- Face Value ₹ 10.0
Pros
- Stock is trading at 0.86 times its book value
Cons
- Company has low interest coverage ratio.
* The pros and cons are machine generated. Pros / cons are based on a checklist to highlight important points. Please exercise caution and do your own analysis.
Peer comparison
Sector: Pharmaceuticals Industry: Pharmaceuticals - Indian - Bulk Drugs & Formln
Quarterly Results
Consolidated Figures in Rs. Crores / View Standalone
Profit & Loss
Consolidated Figures in Rs. Crores / View Standalone
| Mar 2024 | TTM | |
|---|---|---|
| 369 | 347 | |
| 351 | 310 | |
| Operating Profit | 17 | 37 |
| OPM % | 5% | 11% |
| 0 | 0 | |
| Interest | 14 | 15 |
| Depreciation | 15 | 16 |
| Profit before tax | -11 | 7 |
| Tax % | -18% | |
| -9 | 10 | |
| EPS in Rs | -5.73 | 6.44 |
| Dividend Payout % | 0% |
| Compounded Sales Growth | |
|---|---|
| 10 Years: | % |
| 5 Years: | % |
| 3 Years: | % |
| TTM: | % |
| Compounded Profit Growth | |
|---|---|
| 10 Years: | % |
| 5 Years: | % |
| 3 Years: | % |
| TTM: | % |
| Stock Price CAGR | |
|---|---|
| 10 Years: | 14% |
| 5 Years: | 28% |
| 3 Years: | -11% |
| 1 Year: | -14% |
| Return on Equity | |
|---|---|
| 10 Years: | % |
| 5 Years: | % |
| 3 Years: | % |
| Last Year: | % |
Balance Sheet
Consolidated Figures in Rs. Crores / View Standalone
| Mar 2024 | Sep 2024 | |
|---|---|---|
| Equity Capital | 16 | 16 |
| Reserves | 120 | 132 |
| 106 | 83 | |
| 92 | 133 | |
| Total Liabilities | 334 | 364 |
| 148 | 161 | |
| CWIP | 8 | 0 |
| Investments | 0 | 0 |
| 178 | 203 | |
| Total Assets | 334 | 364 |
Cash Flows
Consolidated Figures in Rs. Crores / View Standalone
| Mar 2024 | |
|---|---|
| 4 | |
| -12 | |
| 5 | |
| Net Cash Flow | -3 |
Ratios
Consolidated Figures in Rs. Crores / View Standalone
| Mar 2024 | |
|---|---|
| Debtor Days | 28 |
| Inventory Days | 185 |
| Days Payable | 99 |
| Cash Conversion Cycle | 113 |
| Working Capital Days | 90 |
| ROCE % |
Documents
Announcements
-
Disclosures under Reg. 31(1) and 31(2) of SEBI (SAST) Regulations, 2011.
6 Mar - Disclosure of share pledge by promoter group.
-
Integrated Filing (Financial)
25 Feb - Submission of integrated financial results for Q3 2024.
-
Announcement under Regulation 30 (LODR)-Newspaper Publication
15 Feb - Newspaper publication of Un-Audited Financial Results for the quarter ended 31st December , 2024 declared in the Board Meeting held on 13th February 2025.
- Declaration Of Un-Audited Financial Results For The Quarter Ended 31St December, 2024 13 Feb
-
Board Meeting Outcome for Declaration Of Un-Audited Financial Results For The Quarter Ended 31St December 2024
13 Feb - Board approved unaudited financial results for Q3 2024.
Annual reports
-
Financial Year 2024
from bse
-
Financial Year 2023
from bse
-
Financial Year 2022
from bse
-
Financial Year 2021
from bse
-
Financial Year 2020
from bse
-
Financial Year 2019
from bse
-
Financial Year 2018
from bse
-
Financial Year 2017
from bse
-
Financial Year 2016
from bse
-
Financial Year 2015
from bse
-
Financial Year 2014
from bse
-
Financial Year 2013
from bse
-
Financial Year 2013
from nse
-
Financial Year 2012
from nse
-
Financial Year 2012
from bse
Business Overview:[1]
Company manufactures bulk drugs, organic and inorganic chemicals. It is among the few companies which are World Health Organization -approved Indian companies to be associated with the William J Clinton Foundation for manufacture of anti-malarial drugs. Company supplies artemisinin-based bulk drugs to pharmaceutical companies, for manufacturing anti-malarial formulations